Docoh
Loading...

UROV Urovant Sciences

Employees

Data from SEC filings
Employee count

ESG framework mentions

In last year of SEC filings
Sustainability Accounting Standards Board (SASB)
No mentions
Global Reporting Initiative (GRI)
No mentions
Task Force on Climate-related Financial Disclosures (TCFD)
No mentions
UN Sustainable Development Goals (SDGs)
No mentions

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM
On March 23, 2021, Urovant Sciences Ltd. (the “Company”) held a special general meeting of the Company’s shareholders virtually via live audiocast on the Internet (the “Special Meeting”). At the Special Meeting, the Company’s shareholders considered and voted upon a proposal to approve and adopt an Agreement and Plan of Merger, dated as of November 12, 2020 (as it may be amended from time to time, the “Merger Agreement”) and a related statutory merger agreement (the “Statutory Merger Agreement”) by and among the Company, Sumitovant Biopharma Ltd., a Bermuda exempted company limited by shares (“Sumitovant”), Titan Ltd., a Bermuda exempted company limited by shares and a wholly owned subsidiary of Sumitovant (“Merger Sub”), and, solely with respect to Section 9.13 of the Merger Agreement, Sumitomo Dainippon Pharma Co., Ltd., a company organized under the laws of Japan, and the transactions contemplated by the Merger Agreement and the Statutory Merger Agreement, including a merger pursuant to which Merger Sub will merge with and into the Company (the “Merger”), with the Company surviving the Merger as a wholly owned subsidiary of Sumitovant (the “Merger Proposal”).

The obligations of the parties to the Merger Agreement to consummate the Merger is subject to various conditions set forth in the Merger Agreement, including conditions that (i) holders of at least 66 2/3% of the issued and outstanding common shares of the Company, par value $0.000037453 per share (the “common shares”), entitled to vote on the Merger Proposal and voting at the Special Meeting vote in favor of the Merger Proposal (the “General Shareholder Approval”), and (ii) holders of at least a majority of the outstanding common shares held by shareholders of the Company other than Sumitovant and its affiliates (such shareholders, the “Public Shareholders”) vote in favor of the approval of the Merger Proposal (the “Public Shareholder Approval”).

As of the close of business on January 26, 2021, the record date for the Special Meeting, there were a total of 32,738,709 common shares outstanding and entitled to vote at the Special Meeting. At the Special Meeting, 29,385,871 common shares were present or represented by proxy and, therefore, a quorum was present.

The Merger Proposal was approved and adopted by the affirmative vote of approximately 89.63% of the common shares issued and outstanding as of the close of business on January 26, 2021, the record date for the Special Meeting. The final voting results for the Special Meeting are set forth below.

Voting results for all common shares entitled to vote on the Merger Proposal and voted at the Special Meeting:

ForAgainstAbstain
29,344,79537,5463,530


Voting Results for all common shares held by Public Shareholders entitled to vote on the Merger Proposal and voted at the Special Meeting:

ForAgainstAbstain
6,381,53237,5463,530


Because there were sufficient votes at the Special Meeting to approve the Merger Proposal, the Company did not present for a vote of the Company’s shareholders at the Special Meeting the separate proposal set forth in the Company’s definitive proxy statement for the Special Meeting to approve an adjournment of the Special Meeting, if necessary or appropriate, to solicit additional proxies if there are insufficient votes at the time of the Special Meeting to approve the Merger Proposal.